Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Camille L. Bedrosian Sells 12,425 Shares of Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Camille L. Bedrosian sold 12,425 shares of the company’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $3.47, for a total transaction of $43,114.75. Following the completion of the sale, the insider now owns 194,375 shares in the company, valued at approximately $674,481.25. This trade represents a 6.01 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ:AMLX traded up $0.44 during trading on Wednesday, reaching $3.78. 771,115 shares of the company’s stock traded hands, compared to its average volume of 1,366,939. The company has a 50 day moving average of $3.55 and a 200-day moving average of $4.05. Amylyx Pharmaceuticals, Inc. has a 12 month low of $1.58 and a 12 month high of $7.27. The stock has a market capitalization of $334.92 million, a P/E ratio of -0.99 and a beta of -0.51.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The business had revenue of ($0.67) million during the quarter. Equities research analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AMLX. Blue Trust Inc. lifted its position in Amylyx Pharmaceuticals by 232.1% in the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock worth $26,000 after purchasing an additional 4,883 shares during the period. Fox Run Management L.L.C. acquired a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth $45,000. Alpine Global Management LLC bought a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter worth $45,000. RPO LLC acquired a new position in shares of Amylyx Pharmaceuticals during the fourth quarter worth approximately $46,000. Finally, EntryPoint Capital LLC acquired a new position in Amylyx Pharmaceuticals in the 4th quarter valued at approximately $53,000. Institutional investors own 95.84% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.33.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.